Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.98) per share which beat the analyst consensus estimate of $(1.03) by 4.85 percent. This is a 15.29 percent decrease over losses of $(0.85) per share from the same period last year. The company reported quarterly sales of $20.04 million which beat the analyst consensus estimate of $14.43 million by 38.86 percent.